ARCHIVES

Research Program For Biological Response Modifiers Outlined By DCT board Subcommittee

This article is from The Cancer Letter archive.

Vol. 05 No. 46 | November 16, 1979

Download PDF Visit The Full Archive

Related Articles

FDA Approves Tamoxifen For “Reduction In Incidence,” Avoids Word “Prevention”

November 6, 1998

Study Finds No Link Between Tumor Grade and Relapse Risk

February 25, 2011

Congressman Obey Attacks NCI for Not Supporting Basic Research

January 23, 1976

DCPC Bard Approves $10 Million In Concepts

October 2, 1987

Guest Editorial: Guideline Promises to End Twenty-Year War Over Mass Screening for Prostate Cancer

May 24, 2013

DCT Board Okays 11 Concept Contract Recompetitions

October 26, 1984